- CITATIONS: 1
|Application ||WB, IHC-P, E|
|Other Accession||A2A5Z6, Q9HAU4, Q9PUN2, Q9CUN6|
|Calculated MW||86114 Da|
|Antigen Region||711-740 aa|
|Other Names||E3 ubiquitin-protein ligase SMURF1, hSMURF1, 632-, SMAD ubiquitination regulatory factor 1, SMAD-specific E3 ubiquitin-protein ligase 1, SMURF1, KIAA1625|
|Target/Specificity||This SMURF1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 711-740 amino acids from the C-terminal region of human SMURF1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||SMURF1 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||E3 ubiquitin-protein ligase that acts as a negative regulator of BMP signaling pathway. Mediates ubiquitination and degradation of SMAD1 and SMAD5, 2 receptor-regulated SMADs specific for the BMP pathway. Promotes ubiquitination and subsequent proteasomal degradation of TRAF family members and RHOA. Promotes ubiquitination and subsequent proteasomal degradation of MAVS (PubMed:23087404). Plays a role in dendrite formation by melanocytes (PubMed:23999003).|
|Cellular Location||Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side|
|Tissue Location||Expressed in melanocytes (PubMed:23999003).|
Provided below are standard protocols that you may find useful for product applications.
SMURF1 is an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. This protein interacts with receptor-regulated SMADs specific for the BMP pathway, SMAD1 and SMAD5, in order to trigger their ubiquitination and degradation and thereby their inactivation.
Tajima, Y., et al., J. Biol. Chem. 278(12):10716-10721 (2003).
Suzuki, C., et al., J. Biol. Chem. 277(42):39919-39925 (2002).
Ebisawa, T., et al., J. Biol. Chem. 276(16):12477-12480 (2001).
Zhu, H., et al., Nature 400(6745):687-693 (1999).
Lambris, J., et al., J. Immunol. Methods 27(1):55-59 (1979).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.